Who Paid My Doc
Gregory Watts
Allergy Cleveland, OH Medical Doctor
NPI 1730180209 CMS profile 214834
29001 Cedar Rd, Ste 429, Cleveland, OH 44124
General payments
$535
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, Gregory Watts of Cleveland, OH is reported in the CMS Open Payments database as having received $535 across 9 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 30th percentile of Allergy profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $35 | 2 | |
| 2022 | General | $145 | 2 | |
| 2021 | General | $82 | 1 | |
| 2020 | General | $90 | 2 | |
| 2019 | General | $183 | 2 |
Beside peers
- Gregory Watts
- Allergy median
- Middle half of Allergy
- National median
In program year 2025, general payments to Gregory Watts were reported at $0. Among 526 Allergy profiles paid that year, the median was $1,143 and the middle half received between $226 and $2,504.
Show as a table
| Year | Gregory Watts | Allergy median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $183 | $506 | $151–$1,337 | $163 |
| 2020 | $90 | $409 | $108–$1,162 | $114 |
| 2021 | $82 | $549 | $125–$1,485 | $132 |
| 2022 | $145 | $666 | $161–$1,594 | $149 |
| 2023 | $35 | $780 | $186–$1,916 | $160 |
| 2024 | $0 | $1,031 | $271–$2,196 | $164 |
| 2025 | $0 | $1,143 | $226–$2,504 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 22 drugsPart D claims
1,079
Drug cost
$691,186
Branded share of claims
50.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Dupixent Pen Dupilumab | Brand | 67 | $292,830 | |
| Xolair Omalizumab | Brand | 88 | $240,846 | |
| Tezspire Tezepelumab-Ekko | Brand | 13 | $49,386 | |
| Breo Ellipta Fluticasone/Vilanterol | Brand | 76 | $49,314 | |
| Arnuity Ellipta Fluticasone Furoate | Brand | 33 | $11,892 | |
| Azelastine Hcl | Generic | 235 | $7,243 | |
| Fluticasone-Vilanterol Fluticasone/Vilanterol | Brand | 17 | $6,011 | |
| Epinephrine | Generic | 36 | $5,957 | |
| Dulera Mometasone/Formoterol | Brand | 18 | $5,193 | |
| Qvar Redihaler Beclomethasone Dipropionate | Brand | 15 | $4,964 |
The 10 drugs with the highest cost, of 22 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 16 billing codesPaid by Medicare
$31,433
Medicare patients
295
Services billed
465
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 66% | |
| Arthritis | 56% | |
| Diabetes | 25% | |
| Depression | 24% | |
| Osteoporosis | 24% | |
| Chronic kidney disease | 22% | |
| Ischemic heart disease | 21% | |
| COPD | 19% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
9 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Allergy in Ohio
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.